Compare Lupin Ltd with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs JUBILANT LIFE SCIENCES - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN JUBILANT LIFE SCIENCES LUPIN/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 106.7 14.2 749.0% View Chart
P/BV x 2.4 1.8 136.1% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 LUPIN   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    LUPIN
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
LUPIN/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs986898 109.8%   
Low Rs720618 116.7%   
Sales per share (Unadj.) Rs369.5572.0 64.6%  
Earnings per share (Unadj.) Rs13.436.2 37.0%  
Cash flow per share (Unadj.) Rs37.459.5 62.8%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs303.7301.9 100.6%  
Shares outstanding (eoy) m452.49159.28 284.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.31.3 174.3%   
Avg P/E ratio x63.620.9 304.3%  
P/CF ratio (eoy) x22.812.7 179.2%  
Price / Book Value ratio x2.82.5 111.9%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m386,064120,694 319.9%   
No. of employees `00017.72.4 739.9%   
Total wages/salary Rs m31,51319,260 163.6%   
Avg. sales/employee Rs Th9,453.838,120.6 24.8%   
Avg. wages/employee Rs Th1,782.08,058.4 22.1%   
Avg. net profit/employee Rs Th343.02,414.3 14.2%   
INCOME DATA
Net Sales Rs m167,18291,108 183.5%  
Other income Rs m3,640357 1,018.5%   
Total revenues Rs m170,82291,466 186.8%   
Gross profit Rs m28,82217,390 165.7%  
Depreciation Rs m10,8503,709 292.5%   
Interest Rs m3,0782,198 140.0%   
Profit before tax Rs m18,53411,840 156.5%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,400-2,802 121.3%   
Tax Rs m9,0173,268 275.9%   
Profit after tax Rs m6,0665,770 105.1%  
Gross profit margin %17.219.1 90.3%  
Effective tax rate %48.727.6 176.3%   
Net profit margin %3.66.3 57.3%  
BALANCE SHEET DATA
Current assets Rs m138,53645,848 302.2%   
Current liabilities Rs m61,29920,897 293.3%   
Net working cap to sales %46.227.4 168.7%  
Current ratio x2.32.2 103.0%  
Inventory Days Days8457 147.5%  
Debtors Days Days11251 220.7%  
Net fixed assets Rs m127,51665,498 194.7%   
Share capital Rs m905159 568.1%   
"Free" reserves Rs m136,51747,930 284.8%   
Net worth Rs m137,42248,089 285.8%   
Long term debt Rs m66,41742,429 156.5%   
Total assets Rs m279,494114,685 243.7%  
Interest coverage x7.06.4 109.9%   
Debt to equity ratio x0.50.9 54.8%  
Sales to assets ratio x0.60.8 75.3%   
Return on assets %3.36.9 47.1%  
Return on equity %4.412.0 36.8%  
Return on capital %8.912.4 71.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41412,422 478.3%   
Fx outflow Rs m22,28217,227 129.3%   
Net fx Rs m37,132-4,805 -772.8%   
CASH FLOW
From Operations Rs m16,66011,215 148.5%  
From Investments Rs m-32,825-10,118 324.4%  
From Financial Activity Rs m7,4416,574 113.2%  
Net Cashflow Rs m-8,7247,612 -114.6%  

Share Holding

Indian Promoters % 46.6 45.6 102.2%  
Foreign collaborators % 0.2 3.5 5.7%  
Indian inst/Mut Fund % 11.3 8.7 129.9%  
FIIs % 31.9 21.2 150.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.1 47.9%  
Shareholders   98,259 23,815 412.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   ABBOTT INDIA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  DR. DATSONS LABS  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Nov 11, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS